CSIMarket
 
Cogent Biosciences Inc   (COGT)
Other Ticker:  
 
 
Price: $6.7400 $-0.31 -4.397%
Day's High: $6.97 Week Perf: 6.14 %
Day's Low: $ 6.65 30 Day Perf: -24.1 %
Volume (M): 1,915 52 Wk High: $ 13.50
Volume (M$): $ 12,910 52 Wk Avg: $9.45
Open: $6.84 52 Wk Low: $3.67



 Market Capitalization (Millions $) 581
 Shares Outstanding (Millions) 86
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -178
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 4

Cogent Biosciences Inc
Cogent Biosciences Inc. is a biotechnology company that focuses on the development of precision therapies for genetically driven diseases, with a particular emphasis on oncology. The company is committed to advancing novel small molecule therapies designed to target the underlying cause of diseases. Cogent Biosciences' approach involves identifying genetic mutations and developing drugs to specifically address them, with the aim of providing patients with more effective and personalized treatment options. The company's pipeline includes potential therapies for various cancers, including gastrointestinal stromal tumors and acute myeloid leukemia. Cogent Biosciences aims to make a positive impact on patient lives by advancing innovative therapies that target the root cause of diseases.


   Company Address: 275 Wyman Street Waltham 2451 MA
   Company Phone Number: 945-5576   Stock Exchange / Ticker: NASDAQ COGT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Cogent Biosciences' Bezuclastinib Elicits Promising Results in Rare Mastocytosis Trial, Initiates Next Phase for Approval

Published Thu, Feb 22 2024 7:30 PM UTC

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisCogent Biosciences, a leading biotechnology company specializing in the development of innovative therapies for rare genetic disorders, recently released positive data from Part 1b of their SUMMIT clinical trial. The trial evaluated ...

Equity Market Information

Cogent Biosciences Successfully Raises $225 Million in Private Placement, Bolstering Future Clinical Trials and Prolonging Funding until 2027

Published Wed, Feb 14 2024 12:00 PM UTC

Cogent Biosciences, a leading biotechnology company focusing on the development of precision therapies for genetically driven diseases, has recently announced the completion of an oversubscribed private placement, raising an impressive $225 million. This significant financial boost is expected to support the company through its ongoing registration-directed clinical trials, ...

Product Service News

Cogent Biosciences Sets Path for Precision Therapies Advancements in 2024 and Beyond

Published Tue, Jan 9 2024 1:00 PM UTC

Cogent Biosciences Announces Exciting Milestones for 2024 in Precision Therapies DevelopmentWALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 - Cogent Biosciences, Inc. (Nasdaq: COGT), a leading biotechnology company specializing in the development of precision therapies for genetically defined diseases, is set to embark on a series of key milestones in 2024. The company unve...

Clinical Study

Bezuclastinib Shows Promising Results in Phase 2 SUMMIT Trial for Nonadvanced Systemic Mastocytosis: A Ray of Hope for Patients

Published Sat, Dec 9 2023 6:30 PM UTC



In a significant development in the field of rare diseases, Cogent Biosciences has recently announced positive initial data from its Phase 2 SUMMIT trial, featuring the investigational drug, Bezuclastinib. This breakthrough therapy is designed to address the symptoms and improve the quality of life for patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). The...

Cogent Biosciences Inc

Cogent Biosciences Inc Witnessed Dismal Financial Performance during Q3 2023, Casting Doubt on Sustainability and Alarming Investors 2.

Cogent Biosciences Inc, a major player in the Major Pharmaceutical Preparations industry, recently disclosed its earnings for the third quarter of 2023, revealing a concerning operating deficit of $-59.58 million. This poor financial performance raises serious doubts about the company's ability to sustain profitability and poses a significant risk to investors.
Comparing these results to the same period last year, where Cogent Biosciences Inc reported an operating deficit of $-36.821 million, we can observe a worsening financial situation. The company's attempts to diversify its business models in order to secure consistent revenue sources have clearly not yielded the desired results.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com